Equillium Inc. (EQ)
NASDAQ: EQ
· Real-Time Price · USD
0.37
-0.03 (-7.55%)
At close: May 06, 2025, 3:58 PM
0.37
1.74%
After-hours: May 06, 2025, 07:53 PM EDT
-7.55% (1D)
| Bid | 0.3 |
| Market Cap | 13.13M |
| Revenue (ttm) | 41.09M |
| Net Income (ttm) | -8.07M |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -1.6 |
| Forward PE | -0.33 |
| Analyst | Hold |
| Ask | 0.45 |
| Volume | 222,881 |
| Avg. Volume (20D) | 153,675 |
| Open | 0.39 |
| Previous Close | 0.40 |
| Day's Range | 0.37 - 0.39 |
| 52-Week Range | 0.34 - 1.89 |
| Beta | 2.06 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 12, 2018
Employees 35
Stock Exchange NASDAQ
Ticker Symbol EQ
Website https://equilliumbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for EQ stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 716.10% from the latest price.
Stock Forecasts1 week ago
-2.08%
Equillium shares are trading lower after the compa...
Unlock content with
Pro Subscription
1 month ago
-16.93%
Equillium shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered the price target from $3 to $1.
